Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

9 Meters Biopharma, Inc. - Common Stock (NQ:NMTR)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about 9 Meters Biopharma, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
9 Meters Biopharma, Inc. to Present at 2021 BIO Digital
RALEIGH, NC / ACCESSWIRE / June 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma, Inc. to Present at the Jefferies Virtual Healthcare Conference
RALEIGH, NC / ACCESSWIRE / June 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children (MIS-C) resulting from COVID-19 Infection
- Larazotide supplied to study authors under an FDA-approved Expanded Access Program - - Treatment showed a dramatic drop in inflammatory mediators leading to clinical stabilization, providing... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
News headline image
CORRECTION 9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit
This version of the release contains a corrected hyperlink. RALEIGH, NC / ACCESSWIRE / May 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit
RALEIGH, NC / ACCESSWIRE / May 18, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO,... 
From 9 Meters Biopharma
Via AccessWire
News headline image
9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome
RALEIGH, NC / ACCESSWIRE / May 17, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today that the... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
News headline image
9 Meters Biopharma Provides Business Update and Reports Financial Results for the First Quarter 2021
- Company Closed a $31.5M equity offering in April 2021; provides cash runway into 2023 - Plan to initiate Phase 2 trial with NM-002 in SBS with total stool output as the primary endpoint in Q2... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
News headline image
9 Meters Biopharma, Inc. to Participate in the Truist Securities 7th Annual Life Sciences Summit
RALEIGH, NC / ACCESSWIRE / April 21, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that management will... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
News headline image
9 Meters Biopharma, Inc. Announces Collaboration with the Duke Clinical Research Institute to Support 9 Meters' Program in Short Bowel Syndrome
RALEIGH, NC / ACCESSWIRE / April 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
News headline image
9 Meters Biopharma, Inc. and Celiac Disease Foundation Announce Collaboration to Support Clinical Trial Enrollment in 9 Meters' Phase 3 CeDLara Study
RALEIGH, NC / ACCESSWIRE / April 12, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will... 
From 9 Meters Biopharma
Via AccessWire
Topics Regulatory Compliance
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.